S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
S&P 500   3,870.29 (-0.81%)
DOW   31,391.52 (-0.46%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
BAC   35.53 (-0.73%)
Log in
NASDAQ:PACB

Pacific Biosciences of California Competitors

$34.34
-0.88 (-2.50 %)
(As of 03/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$34.02
Now: $34.34
$35.98
50-Day Range
$30.57
MA: $38.00
$51.15
52-Week Range
$2.20
Now: $34.34
$53.69
Volume3.80 million shs
Average Volume5.42 million shs
Market Capitalization$6.19 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.32

Competitors

Pacific Biosciences of California (NASDAQ:PACB) Vs. TMO, ILMN, A, MTD, BIO, and WAT

Should you be buying PACB stock or one of its competitors? Companies in the sub-industry of "life sciences tools & services" are considered alternatives and competitors to Pacific Biosciences of California, including Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), and Waters (WAT).

Pacific Biosciences of California (NASDAQ:PACB) and Thermo Fisher Scientific (NYSE:TMO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk.

Risk and Volatility

Pacific Biosciences of California has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Thermo Fisher Scientific has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.

Insider and Institutional Ownership

84.9% of Pacific Biosciences of California shares are owned by institutional investors. Comparatively, 87.2% of Thermo Fisher Scientific shares are owned by institutional investors. 11.6% of Pacific Biosciences of California shares are owned by insiders. Comparatively, 0.4% of Thermo Fisher Scientific shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Pacific Biosciences of California and Thermo Fisher Scientific, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pacific Biosciences of California01302.75
Thermo Fisher Scientific041502.79

Pacific Biosciences of California currently has a consensus target price of $43.50, suggesting a potential upside of 26.67%. Thermo Fisher Scientific has a consensus target price of $529.6667, suggesting a potential upside of 14.62%. Given Pacific Biosciences of California's higher probable upside, analysts clearly believe Pacific Biosciences of California is more favorable than Thermo Fisher Scientific.

Valuation and Earnings

This table compares Pacific Biosciences of California and Thermo Fisher Scientific's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacific Biosciences of California$90.89 million68.09$-84,130,000.00($0.55)-62.44
Thermo Fisher Scientific$25.54 billion7.17$3.70 billion$12.3537.42

Thermo Fisher Scientific has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Pacific Biosciences of California and Thermo Fisher Scientific's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pacific Biosciences of California-57.25%-101.30%-32.33%
Thermo Fisher Scientific17.12%21.35%10.55%

Summary

Thermo Fisher Scientific beats Pacific Biosciences of California on 10 of the 14 factors compared between the two stocks.

Pacific Biosciences of California (NASDAQ:PACB) and Illumina (NASDAQ:ILMN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk.

Risk and Volatility

Pacific Biosciences of California has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Illumina has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Insider and Institutional Ownership

84.9% of Pacific Biosciences of California shares are owned by institutional investors. Comparatively, 90.0% of Illumina shares are owned by institutional investors. 11.6% of Pacific Biosciences of California shares are owned by insiders. Comparatively, 0.4% of Illumina shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Pacific Biosciences of California and Illumina, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pacific Biosciences of California01302.75
Illumina38702.22

Pacific Biosciences of California currently has a consensus target price of $43.50, suggesting a potential upside of 26.67%. Illumina has a consensus target price of $365.3158, suggesting a potential downside of 17.16%. Given Pacific Biosciences of California's stronger consensus rating and higher probable upside, analysts clearly believe Pacific Biosciences of California is more favorable than Illumina.

Valuation and Earnings

This table compares Pacific Biosciences of California and Illumina's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacific Biosciences of California$90.89 million68.09$-84,130,000.00($0.55)-62.44
Illumina$3.54 billion18.16$1.00 billion$6.5767.12

Illumina has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Pacific Biosciences of California and Illumina's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pacific Biosciences of California-57.25%-101.30%-32.33%
Illumina19.70%15.93%10.09%

Summary

Illumina beats Pacific Biosciences of California on 9 of the 14 factors compared between the two stocks.

Pacific Biosciences of California (NASDAQ:PACB) and Agilent Technologies (NYSE:A) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk.

Risk and Volatility

Pacific Biosciences of California has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Agilent Technologies has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.

Insider and Institutional Ownership

84.9% of Pacific Biosciences of California shares are owned by institutional investors. 11.6% of Pacific Biosciences of California shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Pacific Biosciences of California and Agilent Technologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pacific Biosciences of California01302.75
Agilent Technologies0101602.62

Pacific Biosciences of California currently has a consensus target price of $43.50, suggesting a potential upside of 26.67%. Agilent Technologies has a consensus target price of $100.4619, suggesting a potential downside of 18.75%. Given Pacific Biosciences of California's stronger consensus rating and higher probable upside, analysts clearly believe Pacific Biosciences of California is more favorable than Agilent Technologies.

Valuation and Earnings

This table compares Pacific Biosciences of California and Agilent Technologies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacific Biosciences of California$90.89 million68.09$-84,130,000.00($0.55)-62.44
Agilent Technologies$5.34 billion7.07$719 million$3.2837.70

Agilent Technologies has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Pacific Biosciences of California and Agilent Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pacific Biosciences of California-57.25%-101.30%-32.33%
Agilent Technologies13.47%21.02%10.73%

Summary

Agilent Technologies beats Pacific Biosciences of California on 8 of the 14 factors compared between the two stocks.

Pacific Biosciences of California (NASDAQ:PACB) and Mettler-Toledo International (NYSE:MTD) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk.

Risk and Volatility

Pacific Biosciences of California has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Mettler-Toledo International has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.

Insider and Institutional Ownership

84.9% of Pacific Biosciences of California shares are owned by institutional investors. Comparatively, 93.2% of Mettler-Toledo International shares are owned by institutional investors. 11.6% of Pacific Biosciences of California shares are owned by insiders. Comparatively, 3.2% of Mettler-Toledo International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Pacific Biosciences of California and Mettler-Toledo International, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pacific Biosciences of California01302.75
Mettler-Toledo International47101.75

Pacific Biosciences of California currently has a consensus target price of $43.50, suggesting a potential upside of 26.67%. Mettler-Toledo International has a consensus target price of $868.0833, suggesting a potential downside of 22.67%. Given Pacific Biosciences of California's stronger consensus rating and higher probable upside, analysts clearly believe Pacific Biosciences of California is more favorable than Mettler-Toledo International.

Valuation and Earnings

This table compares Pacific Biosciences of California and Mettler-Toledo International's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacific Biosciences of California$90.89 million68.09$-84,130,000.00($0.55)-62.44
Mettler-Toledo International$3.01 billion8.73$561.11 million$22.7749.30

Mettler-Toledo International has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Pacific Biosciences of California and Mettler-Toledo International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pacific Biosciences of California-57.25%-101.30%-32.33%
Mettler-Toledo International19.36%144.89%21.11%

Summary

Mettler-Toledo International beats Pacific Biosciences of California on 8 of the 14 factors compared between the two stocks.

Pacific Biosciences of California (NASDAQ:PACB) and Bio-Rad Laboratories (NYSE:BIO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk.

Analyst Ratings

This is a summary of current ratings and price targets for Pacific Biosciences of California and Bio-Rad Laboratories, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pacific Biosciences of California01302.75
Bio-Rad Laboratories00403.00

Pacific Biosciences of California currently has a consensus target price of $43.50, suggesting a potential upside of 26.67%. Bio-Rad Laboratories has a consensus target price of $646.00, suggesting a potential upside of 9.27%. Given Pacific Biosciences of California's higher probable upside, analysts clearly believe Pacific Biosciences of California is more favorable than Bio-Rad Laboratories.

Risk and Volatility

Pacific Biosciences of California has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Profitability

This table compares Pacific Biosciences of California and Bio-Rad Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pacific Biosciences of California-57.25%-101.30%-32.33%
Bio-Rad Laboratories147.91%3.77%2.74%

Insider and Institutional Ownership

84.9% of Pacific Biosciences of California shares are owned by institutional investors. Comparatively, 63.0% of Bio-Rad Laboratories shares are owned by institutional investors. 11.6% of Pacific Biosciences of California shares are owned by insiders. Comparatively, 27.5% of Bio-Rad Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Pacific Biosciences of California and Bio-Rad Laboratories' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacific Biosciences of California$90.89 million68.09$-84,130,000.00($0.55)-62.44
Bio-Rad Laboratories$2.31 billion7.63$1.76 billion$7.0683.74

Bio-Rad Laboratories has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Summary

Bio-Rad Laboratories beats Pacific Biosciences of California on 10 of the 14 factors compared between the two stocks.

Waters (NYSE:WAT) and Pacific Biosciences of California (NASDAQ:PACB) are both computer and technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations for Waters and Pacific Biosciences of California, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Waters58101.71
Pacific Biosciences of California01302.75

Waters presently has a consensus price target of $219.4545, suggesting a potential downside of 19.92%. Pacific Biosciences of California has a consensus price target of $43.50, suggesting a potential upside of 26.67%. Given Pacific Biosciences of California's stronger consensus rating and higher possible upside, analysts plainly believe Pacific Biosciences of California is more favorable than Waters.

Volatility & Risk

Waters has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Pacific Biosciences of California has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500.

Profitability

This table compares Waters and Pacific Biosciences of California's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Waters22.61%-349.31%21.11%
Pacific Biosciences of California-57.25%-101.30%-32.33%

Insider and Institutional Ownership

91.8% of Waters shares are held by institutional investors. Comparatively, 84.9% of Pacific Biosciences of California shares are held by institutional investors. 1.5% of Waters shares are held by company insiders. Comparatively, 11.6% of Pacific Biosciences of California shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Waters and Pacific Biosciences of California's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Waters$2.41 billion7.08$592.20 million$8.9930.48
Pacific Biosciences of California$90.89 million68.09$-84,130,000.00($0.55)-62.44

Waters has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.


Pacific Biosciences of California Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Thermo Fisher Scientific logo
TMO
Thermo Fisher Scientific
2.3$462.11-0.6%$183.15 billion$25.54 billion37.88Dividend Increase
Illumina logo
ILMN
Illumina
1.7$441.01-1.2%$64.34 billion$3.54 billion102.32
Agilent Technologies logo
A
Agilent Technologies
1.8$123.64-0.7%$37.76 billion$5.34 billion53.76
Mettler-Toledo International logo
MTD
Mettler-Toledo International
1.3$1,122.57-1.1%$26.28 billion$3.01 billion47.23Decrease in Short Interest
Bio-Rad Laboratories logo
BIO
Bio-Rad Laboratories
1.3$591.22-1.0%$17.64 billion$2.31 billion5.06
Waters logo
WAT
Waters
1.5$274.03-1.1%$17.04 billion$2.41 billion34.13Decrease in Short Interest
Bio-Techne logo
TECH
Bio-Techne
1.8$375.44-0.8%$14.57 billion$738.69 million60.07Analyst Upgrade
Charles River Laboratories International logo
CRL
Charles River Laboratories International
1.5$287.46-0.7%$14.31 billion$2.62 billion47.91
PerkinElmer logo
PKI
PerkinElmer
1.9$127.53-1.7%$14.28 billion$2.88 billion34.65
Bruker logo
BRKR
Bruker
2.1$62.32-0.3%$9.57 billion$2.07 billion61.10Decrease in Short Interest
Luminex logo
LMNX
Luminex
2.0$29.89-5.7%$1.47 billion$334.64 million76.64Insider Selling
Fluidigm logo
FLDM
Fluidigm
1.8$4.34-9.4%$323.53 million$117.24 million-6.48
Harvard Bioscience logo
HBIO
Harvard Bioscience
1.1$4.32-2.3%$172.27 million$116.18 million-24.00
aTyr Pharma logo
LIFE
aTyr Pharma
1.5$4.54-2.9%$46.24 million$420,000.00-1.71Increase in Short Interest
News Coverage
Gap Down
This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.